Yasser's Gross Exaggerations, I mean BS, equates to valuing AEGR with the likes of Apple, Exxon, and Walmart
it's tough enough justifying the current market cap 2.1 billion, err 2,133 million, on less than 2 million in annual revenue, let alone trying to do so on the basis of a single drug with extremely limited patient population, wiki estimates one in a million are born with homozygous familial hypercholesterolemia (HoFH).
317 potential prescriptions in the USA, and 504 potential prescriptions in the EU...to reach full potential you have to assume their insurance companies will pay the tab for the $300K per annum prescription, when the competition offers $100K per annum treatment. If their insurance companies refuse to pay for the high priced drugs,,,without insurance coverage, 3-4 of of those afflicted will have the resources to pay out of pocket.
There you go lying again. 317 potential prescriptions in the USA? Based on what fiction rag? There are 3,000 diagnosed cases reported in the USA of HoFH. Why can't you get that brought your pea sized brain. I know you pretend it is a vast conspiracy across thousands of doctors and hospitals, but it isn't.
You live in a fantasy world. That's why you lost you 100-share short.